- Home
- REFI vs PRQR Comparison
REFI vs PRQR Comparison
Compare REFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- PRQR
- Stock Information
- Founded
- REFI 2021
- PRQR 2012
- Country
- REFI United States
- PRQR Netherlands
- Employees
- REFI N/A
- PRQR N/A
- Industry
- REFI Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- PRQR Health Care
- Exchange
- REFI Nasdaq
- PRQR Nasdaq
- Market Cap
- REFI 291.9M
- PRQR 309.5M
- IPO Year
- REFI 2021
- PRQR 2014
- Fundamental
- Price
- REFI $14.85
- PRQR $1.55
- Analyst Decision
- REFI Strong Buy
- PRQR Strong Buy
- Analyst Count
- REFI 3
- PRQR 6
- Target Price
- REFI $20.00
- PRQR $9.00
- AVG Volume (30 Days)
- REFI 112.2K
- PRQR 678.2K
- Earning Date
- REFI 05-07-2025
- PRQR 05-08-2025
- Dividend Yield
- REFI 13.87%
- PRQR N/A
- EPS Growth
- REFI N/A
- PRQR N/A
- EPS
- REFI 1.88
- PRQR N/A
- Revenue
- REFI $56,790,054.00
- PRQR $21,212,711.00
- Revenue This Year
- REFI $17.87
- PRQR $6.44
- Revenue Next Year
- REFI N/A
- PRQR N/A
- P/E Ratio
- REFI $7.90
- PRQR N/A
- Revenue Growth
- REFI 4.68
- PRQR 85.91
- 52 Week Low
- REFI $12.76
- PRQR $1.07
- 52 Week High
- REFI $16.47
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- REFI 59.49
- PRQR 50.51
- Support Level
- REFI $14.50
- PRQR $1.50
- Resistance Level
- REFI $14.81
- PRQR $2.02
- Average True Range (ATR)
- REFI 0.27
- PRQR 0.17
- MACD
- REFI 0.12
- PRQR 0.03
- Stochastic Oscillator
- REFI 93.44
- PRQR 48.04
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.